Overview

Omecamtiv Mecarbil Post-trial Access Study

Status:
Withdrawn
Trial end date:
2026-11-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to provide access to omecamtiv mecarbil for participants who have completed GALACTIC-HF 20110203.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Cytokinetics